An interventional study of Music therapy intervention in Lung Cancer (Suspected or Confirmed), sponsored by Oncology Institute of Southern Switzerland. Recruiting at 1 site in Switzerland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-08.
Sponsored by Oncology Institute of Southern Switzerland · Not applicable, Interventional, and Supportive care
Among 98 studies in Lung Neoplasms with a site in Switzerland — 26 open to participants now, 32 under way, 11 of them phase 3. Lung Neoplasms · Switzerland.
Among the 98 studies in Lung Neoplasms with a site in Switzerland, this one is the 47th largest by planned enrollment of the 77 interventional ones that give a count, is one of 5 that started in 2026, is one of 13 with no phase, reaches primary completion later than 12 of the 31 other live ones, and was the 94th registered.
5,422 studies on the registry are indexed under Lung Neoplasms; 1,346 are open to participants now.
Browse Lung Neoplasms studies →26 of the 98 studies in Lung Neoplasms with a site in Switzerland are open now. Recruiting first, the newest first:
Intuitive Surgical · Sites in Switzerland, Germany, United Kingdom
Ages 18+
Oncology Institute of Southern Switzerland · Sites in Switzerland
Ages 18+
Bristol-Myers Squibb · Sites in Switzerland, United States, Argentina and 22 more countries
Ages 18+
Hoffmann-La Roche · Sites in Switzerland, United States, Argentina and 25 more countries
Ages 18+
Intuitive Surgical · Sites in Switzerland, France, Germany and 1 more country
Ages 18+
A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →
Of the 996 Lung Neoplasms studies recruiting now, 683 (69%) set no upper age limit and 142 (14%) stop at 75 or younger; 45 take children under 18; 142 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
98 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 25 · Phase 3 31 · Phase 4 5
First in 1995; this study’s year is marked. 5 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 74 is above the median of 60 across 3,656 interventional studies indexed under Lung Neoplasms.
Median enrollment 136 across the 77 interventional studies, 294 across the 20 observational. Of the 61 that completed or were terminated, 18 (30%) have results posted.
This tab as a report to print or save as PDF → With an account.
40 of 98 have an industry lead sponsor. The 10 most frequent:
Oncology Institute of Southern Switzerland is the lead sponsor of 19 studies on the registry; 9 are open to participants now.
Oncology Institute of Southern Switzerland has 2 studies filed under Lung Neoplasms — fewer than ten, so there is no comparison to draw.
6 of the studies in Lung Neoplasms with a site in Switzerland that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05920356Phase 3AmgenA Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202) | 2027-06-30 |
| NCT06119581Phase 3Eli Lilly and CompanyA Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer | 2027-11 |
| NCT07099898Phase 3GlaxoSmithKlineA Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC) [EMBOLD SCLC-301] | 2027-11-05 |
| NCT03979170University Hospital, GenevaPatient-derived Organoids of Lung Cancer to Test Drug Response | 2026-12-30 |
| NCT07398027Carolin SteinackPost-Market Study of Transbronchial Cryo-assisted RFA During Robotic Bronchoscopy With Subsequent Surgical Resection | 2027-03 |
Add all 6 to your calendar (.ics) → With an account.
Among the 98 studies in Lung Neoplasms with a site in Switzerland, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study aims at evaluating whether music therapy intervention is effective in decreasing psychological (distress) and physical symptoms (pain) in patients with suspected or diagnosed lung cancer undergoing minimally invasive lung surgery.
A diagnosis of cancer may result in extensive emotional, physical and social suffering. Moreover, surgical treatment of lung cancer represents itself a stressful event. It is important that cancer care incorporates services that help meet patients' psychological, social and spiritual needs. Music therapy interventions have been used to alleviate symptoms and treatment side effects in cancer patients and their efficacy has been demonstrated in various settings. Within the distinction between music therapy (a personalized approach based on the interaction with a trained music therapist) and music medicine (with pre-recorded music), the best efficacy results have been reported with music therapy.
The use of music listening is growing in the field of music therapy intervention because of the impact musical contents can have on physiological, psychological and behavioural levels.
The primary objective of this study is to evaluate whether music therapy intervention is effective in decreasing psychological (distress) and physical symptoms (pain) in patients with suspected or diagnosed lung cancer undergoing minimally invasive lung surgery. Secondary objectives are the evaluation of the decrease of the serum cortisol as biomarker of stress and the request of additional doses of analgesics for pain control.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients with suspected or diagnosed lung cancer undergoing minimally invasive lung resection will be treated with classical music therapy and standard of care.
Other: Music therapy intervention
Patients with suspected or diagnosed lung cancer undergoing minimally invasive lung resection will be treated with standard of care only.
Patient randomized to experimental Arm A will receive a classical music therapy intervention throughout the duration of their hospital stay for a minimally invasive lung resection.
Level of distress
Change of the level of distress on the Distress thermometer
Time frame: From the day of surgery until the day of discharge from the hospital (in average 6 days after surgery)
Pain intensity
Change of pain intensity on the numerical scale
Time frame: From the day of surgery until the day of discharge from the hospital (in average 6 days after surgery)
Serum cortisol levels
Change in the levels of serum cortisol measured in the morning
Time frame: From the day of surgery until the day of discharge from the hospital (in average 6 days after surgery)
Additional doses of analgesics for pain control
Number of additional doses of analgesics administered for pain control per day
Time frame: From the day of surgery until the day of discharge from the hospital (in average 6 days after surgery)
Plan to share: Undecided
No publications or documents are linked to this record.
Started Jun 2026 (actual). Primary completion is estimated for Dec 2027, 18 months after the start.
Of 864 non-industry interventional studies with no phase under Lung Neoplasms, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 68. This study's planned 18 months is below that.
Counting every sponsor, half of 915 studies reached it within 34 months; a quarter within 15 and three quarters within 67.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Oncology Institute of Southern Switzerland